Equity Profile

CLDX

Celldex Therapeutics, Inc.

Health CareBiotechnology$2.5B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and is closely watched by investors.

$-1.10

Revenue Growth

While specific revenue estimates are not available, any growth in revenue can signal the effectiveness of their product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $2 billion, it operates in the health care sector, which is increasingly important as the demand for advanced medical treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

In Q1-2026, Celldex reported an EPS of $-1.18, missing estimates by 6.88%. The stock reacted negatively, dropping 3.11% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for their lead product candidates.
Commitment to managing costs effectively to improve future EPS.
Plans to provide more transparency on upcoming trial results.

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, especially given the company's recent history of missing EPS estimates. The market will be looking for any signs of improvement in clinical trial progress.

Bull Case

If Celldex can report better-than-expected EPS and provide positive updates on clinical trials, it could lead to a significant stock rally, reflecting investor optimism.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide clear progress on its clinical trials, it could lead to further declines in stock price.

Key Metrics to Watch

EPS (Earnings Per Share)

$-1.10

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue can signal the effectiveness of their product pipeline.

Clinical Trial Updates

N/A

Updates on ongoing clinical trials can significantly impact investor sentiment and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trial results?

The market will heavily weigh this information as it directly impacts the perceived value of the company's pipeline.

Will the company provide guidance on expected EPS for the next quarter?

Clear guidance can help set investor expectations and influence stock performance in the near term.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive clinical trial results, which could significantly enhance the company's valuation.

Supporting Evidence

The options market is pricing a large move, indicating that investors expect significant news.

Celldex has a history of surprising investors with better-than-expected trial outcomes.

Recent insider activity, while not reported, may suggest confidence in upcoming results.

Key Risk

If clinical trial updates indicate significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around the company's ability to improve its financial performance and advance its clinical programs.

Bull Confirmed If

A reported EPS of $-1.10 or better, along with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.20, coupled with no significant clinical trial progress, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.62%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, suggesting that investors expect volatility around the earnings report.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats EPS expectations, history suggests a potential stock increase of around 2.01%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

If the company misses EPS estimates again, history suggests a potential decline of about 5.80%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trial results.
2Management's commentary on cost management strategies.
3Details on any new partnerships or collaborations.
4Insights into the competitive landscape and how Celldex plans to position itself.
5Guidance on expected EPS for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and is closely watched by investors.

$-1.10

Revenue Growth

While specific revenue estimates are not available, any growth in revenue can signal the effectiveness of their product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

In Q1-2026, Celldex reported an EPS of $-1.18, missing estimates by 6.88%. The stock reacted negatively, dropping 3.11% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for their lead product candidates.
Commitment to managing costs effectively to improve future EPS.
Plans to provide more transparency on upcoming trial results.

Expectations

Wall Street Expectations

Bull Case

If Celldex can report better-than-expected EPS and provide positive updates on clinical trials, it could lead to a significant stock rally, reflecting investor optimism.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide clear progress on its clinical trials, it could lead to further declines in stock price.

Key Metrics to Watch

EPS (Earnings Per Share)

$-1.10

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue can signal the effectiveness of their product pipeline.

Clinical Trial Updates

N/A

Updates on ongoing clinical trials can significantly impact investor sentiment and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trial results?

The market will heavily weigh this information as it directly impacts the perceived value of the company's pipeline.

Will the company provide guidance on expected EPS for the next quarter?

Clear guidance can help set investor expectations and influence stock performance in the near term.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive clinical trial results, which could significantly enhance the company's valuation.

Supporting Evidence

The options market is pricing a large move, indicating that investors expect significant news.

Celldex has a history of surprising investors with better-than-expected trial outcomes.

Recent insider activity, while not reported, may suggest confidence in upcoming results.

Key Risk

If clinical trial updates indicate significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around the company's ability to improve its financial performance and advance its clinical programs.

Bull Confirmed If

A reported EPS of $-1.10 or better, along with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.20, coupled with no significant clinical trial progress, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.62%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, suggesting that investors expect volatility around the earnings report.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats EPS expectations, history suggests a potential stock increase of around 2.01%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

If the company misses EPS estimates again, history suggests a potential decline of about 5.80%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trial results.
2Management's commentary on cost management strategies.
3Details on any new partnerships or collaborations.
4Insights into the competitive landscape and how Celldex plans to position itself.
5Guidance on expected EPS for the next quarter.